Literature DB >> 17163294

Psychotic disorder induced by oxybutynin: Presentation of two cases.

Murat Gulsun1, Murat Pinar, Unal Sabanci.   

Abstract

Anticholinergic agents are muscarinic receptor antagonists that suppress the activity of the acetylcholine system in the brain. Some of these agents also increase the concentration of dopamine in the synaptic cleft, which may result in psychotic symptoms. Oxybutynin is an antimuscarinic drug that may have adverse effects on the CNS, including memory impairment, confusion, delirium and hallucinations in elderly patients. To date, several case reports have been published about the association between oxybutynin and psychotic symptoms in elderly subjects, but we were unable to find any case reports describing oxybutynin-induced psychotic disorders in young people. Here we report on two patients, a 7-year-old boy and a 21-year-old man, who developed a brief psychotic disorder that may have been caused by oxybutynin. The first patient was kept under observation with vital functions supported but no medication. All his psychotic symptoms regressed and his general condition improved. The second patient was treated with olanzapine 10 mg/day. His psychotic symptoms resolved within 3 weeks. Our two case reports provide evidence that oxybutynin may induce psychotic disorders, and in younger patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17163294     DOI: 10.2165/00044011-200626100-00007

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  23 in total

1.  Acute anticholinergic syndrome due to Jimson seed ingestion. Clinical and laboratory observation in six cases.

Authors:  J R Mikolich; G W Paulson; C J Cross
Journal:  Ann Intern Med       Date:  1975-09       Impact factor: 25.391

2.  New adverse effect of oxybutynin: "night terror".

Authors:  M E Valsecia; L A Malgor; J H Espíndola; D H Carauni
Journal:  Ann Pharmacother       Date:  1998-04       Impact factor: 3.154

3.  Comparison of calcium antagonist properties of antispasmotic agents.

Authors:  S B Malkowicz; A J Wein; M R Ruggieri; R M Levin
Journal:  J Urol       Date:  1987-09       Impact factor: 7.450

4.  Treatment of scopolamine-induced delirium.

Authors:  K C Ullman; R H Groh; F W Wolff
Journal:  Lancet       Date:  1970-01-31       Impact factor: 79.321

5.  Benztropine psychosis.

Authors:  J V Ananth; R C Jain
Journal:  Can Psychiatr Assoc J       Date:  1973-10

6.  The reversal of anticholinergic drug-induced delirium and coma with physostigmine.

Authors:  J F Heiser; J C Gillin
Journal:  Am J Psychiatry       Date:  1971-02       Impact factor: 18.112

Review 7.  The central effects of scopolamine in man.

Authors:  D J Safer; R P Allen
Journal:  Biol Psychiatry       Date:  1971       Impact factor: 13.382

8.  Toxic psychosis induced by benzhexol hydrochloride.

Authors:  J V Ananth
Journal:  Can Med Assoc J       Date:  1970-10-10       Impact factor: 8.262

Review 9.  Drug therapy. Anticholinergics.

Authors:  D J Greenblatt; R I Shader
Journal:  N Engl J Med       Date:  1973-06-07       Impact factor: 91.245

10.  Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers.

Authors:  A Pietzko; W Dimpfel; U Schwantes; P Topfmeier
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

View more
  10 in total

Review 1.  Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder.

Authors:  Michael B Chancellor; David R Staskin; Gary G Kay; Bobby W Sandage; Michael G Oefelein; Jack W Tsao
Journal:  Drugs Aging       Date:  2012-04-01       Impact factor: 3.923

Review 2.  Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients.

Authors:  Dustin Pagoria; R Corey O'Connor; Michael L Guralnick
Journal:  Curr Urol Rep       Date:  2011-10       Impact factor: 3.092

Review 3.  Antimuscarinics for the treatment of overactive bladder: understanding the role of muscarinic subtype selectivity.

Authors:  Karin Glavind; Michael Chancellor
Journal:  Int Urogynecol J       Date:  2011-04-06       Impact factor: 2.894

4.  Delirium following fesoterodine treatment for urgency incontinence in an 89-year old man.

Authors:  Jeannie Medeiros Charbonneau; Rania Bisset; Patrick Viet-Quoc Nguyen
Journal:  Can Urol Assoc J       Date:  2016-07-12       Impact factor: 1.862

Review 5.  Managing Urinary Incontinence in Patients with Dementia: Pharmacological Treatment Options and Considerations.

Authors:  Susie Orme; Vikky Morris; William Gibson; Adrian Wagg
Journal:  Drugs Aging       Date:  2015-07       Impact factor: 3.923

Review 6.  Drugs with anticholinergic properties: cognitive and neuropsychiatric side-effects in elderly patients.

Authors:  Iacopo Cancelli; Massimiliano Beltrame; Gian Luigi Gigli; Mariarosaria Valente
Journal:  Neurol Sci       Date:  2009-02-20       Impact factor: 3.307

Review 7.  The Pharmacology of Visual Hallucinations in Synucleinopathies.

Authors:  Mirella Russo; Claudia Carrarini; Fedele Dono; Marianna Gabriella Rispoli; Martina Di Pietro; Vincenzo Di Stefano; Laura Ferri; Laura Bonanni; Stefano Luca Sensi; Marco Onofrj
Journal:  Front Pharmacol       Date:  2019-12-09       Impact factor: 5.810

Review 8.  Urinary Incontinence and Alzheimer's Disease: Insights From Patients and Preclinical Models.

Authors:  Sarah N Bartolone; Prasun Sharma; Michael B Chancellor; Laura E Lamb
Journal:  Front Aging Neurosci       Date:  2021-12-17       Impact factor: 5.750

Review 9.  Antimuscarinics for the treatment of overactive bladder: a review of central nervous system effects.

Authors:  Adam P Klausner; William D Steers
Journal:  Curr Urol Rep       Date:  2007-11       Impact factor: 2.862

Review 10.  Rationale for the use of anticholinergic agents in overactive bladder with regard to central nervous system and cardiovascular system side effects.

Authors:  Bülent Cetinel; Bulent Onal
Journal:  Korean J Urol       Date:  2013-12-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.